Arizona State Retirement System Lowers Stake in Johnson & Johnson $JNJ

Key Points

• Arizona State Retirement System trimmed its Johnson & Johnson stake by 3.3% in Q4, selling 23,356 shares to hold 679,300 shares worth $140.58 million, about 0.8% of its portfolio and the firm's 15th largest position.
• Johnson & Johnson beat Q1 estimates (EPS $2.70 vs. $2.68; revenue $24.06B vs. $23.60B), issued FY2026 guidance of $11.45–$11.65 EPS, and raised its quarterly dividend to $1.34 ($5.36 annual; yield ~2.4%).
• Insiders sold 30,142 shares in the last quarter (notably EVPs Timothy Schmid and Vanessa Broadhurst) totaling about $7.36 million, while insiders own roughly 0.16% of the company.

Arizona State Retirement System trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 679,300 shares of the company's stock after selling 23,356 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Arizona State Retirement System's investment portfolio, making the stock its 15th biggest position. Arizona State Retirement System's holdings in Johnson & Johnson were worth $140,581,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after buying an additional 956,239 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after buying an additional 835,146 shares during the period. Legal & General Group Plc boosted its stake in shares of Johnson & Johnson by 2.8% in the 3rd quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after buying an additional 532,790 shares during the period. Amundi boosted its stake in shares of Johnson & Johnson by 19.3% in the 3rd quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after buying an additional 2,163,838 shares during the period. Finally, Raymond James Financial Inc. boosted its stake in shares of Johnson & Johnson by 7.3% in the 3rd quarter. Raymond James Financial Inc. now owns 10,137,651 shares of the company's stock valued at $1,879,718,000 after buying an additional 690,887 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on JNJ shares. Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 15th. Weiss Ratings cut shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b)" rating in a report on Friday. Scotiabank restated an "outperform" rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Bank of America upped their price target on Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 15th. Finally, TD Cowen began coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They set a "buy" rating and a $250.00 price target for the company. Eighteen investment analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $252.48.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as a potential first approved treatment for warm autoimmune hemolytic anemia — a faster review (≈6 months) raises the chance of an earlier revenue stream and de‑risked late‑stage pipeline value. FDA grants Priority Review for IMAAVY (nipocalimab-aahu)
• Positive Sentiment: JNJ agreed to acquire Atraverse Medical to bolster its left‑heart access and radiofrequency cardiac‑ablation portfolio — a strategic MedTech tuck‑in that can expand procedure addressable market and device pipeline synergies. J&J agrees to acquire Atraverse Medical
• Positive Sentiment: Management says AI is cutting the time to generate drug leads by ~50% — efficiency gains in early discovery could lower R&D cost and accelerate pipeline progression, improving longer‑term margin and pipeline optionality. J&J sees AI halving the time to generate drug development leads
• Positive Sentiment: High‑profile endorsement and dividend appeal — Jim Cramer highlighted JNJ’s strong pipeline and InsiderMonkey/Reddit lists include JNJ among quality dividend picks, supporting interest from income and fundamentals‑focused investors. Jim Cramer Says Johnson & Johnson “Has the Best Pipeline of Potential Blockbusters” Johnson & Johnson – Among the 10 Best Quality Dividend Stocks to Buy According to Reddit
• Neutral Sentiment: Investor outreach: JNJ will present at Bernstein’s Strategic Decisions Conference (May 27) — a chance for management to update strategy and reassure investors, but typically not a catalyst unless material new guidance or announcements are made. Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference
• Neutral Sentiment: Sector headlines (Goldman on UnitedHealth and healthcare ETFs) may be diverting flows across the group — this can mute individual stock moves like JNJ as investors rotate within healthcare. Goldman Sachs Lifts UnitedHealth Target Price
• Neutral Sentiment: JNJ’s reported participation in TrumpRX and other political/PR items could introduce reputational sensitivity for some investors, but so far this is unlikely to materially change fundamentals. Johnson & Johnson Joins TrumpRX

Johnson & Johnson Trading Down 1.0%

NYSE JNJ opened at $225.23 on Tuesday. The stock has a market capitalization of $542.17 billion, a P/E ratio of 26.04, a P/E/G ratio of 2.23 and a beta of 0.34. Johnson & Johnson has a 52-week low of $146.12 and a 52-week high of $251.71. The firm has a 50-day moving average price of $239.82 and a 200 day moving average price of $219.11. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts expect that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson's dividend payout ratio (DPR) is currently 60.12%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.